August 5 2026

Consolidated Financial Results
for the Three Months Ended June 30, 2026
(Under Japanese GAAP)

Company name: TOHO HOLDINGS CO., LTD.
Listing: Tokyo Stock Exchange
Securities code: 8129
URL: https://www.tohohd.co.jp/en/
Representative: Hiromi Edahiro / Representative Director, President and CEO
Inquiries: Makoto Kawamura / Senior Executive Corporate Officer and General Manager, Corporate Strategy Division
Telephone: +81-3-6838-2803
Scheduled date to commence dividend payments: —
Preparation of supplementary material on financial results: Yes
Holding of financial results briefing: None

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the three months ended June 30, 2026
(from April 1, 2026 to June 30, 2026)

(1) Consolidated operating results (cumulative) (Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
Three months ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
June 30, 2026	397,774	5.8	2,465	-35.8	3,810	-14.1	2,355	-29.8
June 30, 2025	375,813	0.7	3,842	68.6	4,436	51.5	3,353	85.8

Note: Comprehensive income For the three months ended June 30, 2026: ¥853 million [-69.9%]
For the three months ended June 30, 2025: ¥2,836 million [39.5%]

	Basic earnings per share	Diluted earnings per share
Three months ended	Yen	Yen
June 30, 2026	36.24	35.93
June 30, 2025	53.61	49.79

(2) Consolidated financial position

	Total assets	Net assets	Equity-to-asset ratio
As of	Millions of yen	Millions of yen	%
June 30, 2026	773,239	266,193	34.4
March 31, 2026	740,781	271,560	36.6

Reference: Equity As of June 30, 2026: ¥265,980 million
As of March 31, 2026: ¥271,310 million

2. Cash dividends

	Annual dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2026	–	45.00	–	120.00	165.00
Fiscal year ending March 31, 2027	–				
Fiscal year ending March 31, 2027 (Forecast)		90.00	–	90.00	180.00

Note: Revision to the forecast of cash dividends most recently announced: None

3. Consolidated financial forecast for fiscal year ending March 31, 2027 (from April 1, 2026 to March 31, 2027)

(Percentages indicate the rate of change compared with the preceding fiscal year.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Net income per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
First Half	797,000	3.8	6,300	-13.2	7,200	-13.6	4,200	-32.7	64.45
Full year	1,601,000	3.1	14,800	-10.9	16,600	-0.2	12,900	-25.6	197.67

Note: Revision of consolidated financial forecast most recently announced: None

*** Notes**

(1) Significant changes in the scope of consolidation during the period: None
Newly included: ―
Excluded: ―

(2) Adoption of accounting treatment specific to the preparation of quarterly consolidated financial statements: None

(3) Changes in accounting policies, changes in accounting estimates, and restatement
(i) Changes in accounting policies due to revisions to accounting standards and other regulations: None
(ii) Changes in accounting policies due to other reasons: None
(iii) Changes in accounting estimates: None
(iv) Restatement: None

(4) Number of issued shares (common shares)

(i) Total number of issued shares at the end of the period (including treasury shares)

As of June 30, 2026	73,025,942 shares
As of March 31, 2026	73,025,942 shares

(ii) Number of treasury shares at the end of the period

As of June 30, 2026	7,673,770 shares
As of March 31, 2026	8,324,319 shares

(iii) Average number of shares outstanding during the period (cumulative from the beginning of the fiscal year)

Three months ended June 30, 2026	64,987,511 shares
Three months ended June 30, 2025	62,550,584 shares

* Review of the Japanese-language originals of the attached consolidated quarterly financial statements by certified public accountants or an audit firm: None

* Proper use of earnings forecasts, and other special matters

Any forward-looking statements contained in this report, including performance projections, are based on information currently available to the Company as well as certain assumptions that the Company determined to be rational at the time of the release of this report, and it is not intended that the Company undertake to achieve such results. Actual results may differ significantly from the projections above, due to a variety of factors.

Please refer to Explanation of Consolidated Financial Forecasts and Other Forward-Looking Information on page 4 of this report (the attached document) for the suppositions on which the performance projections are based and points that have to be borne in mind for the use of such projections.

〇Contents of Attached Document

1. Qualitative Information on Financial Results for the Three Months Ended June 30, 2026

(1) Explanation of Management Results

During the first quarter of the current fiscal year, the prescription pharmaceuticals market saw a 4.02% reduction in NHI drug prices, based on pharmaceutical prices, following the NHI drug price revisions in April 2026. At the same time, to ensure a stable supply of pharmaceuticals, exceptions – such as raising or maintaining the prices of certain drugs in conjunction with the repricing measures of unprofitable products – have also been implemented. In addition, based on the revised Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices passed last year, efforts are underway to strengthen the stable supply system for prescription pharmaceuticals and to enhance pharmacy functions, including the partial outsourcing of dispensing operations.

In April of this year, our Group formulated its Medium-term Management Plan 2026-2028, titled “Soaring into the Next Generation,” which covers a three-year period beginning in fiscal year 2026. In this Medium-term Management Plan, we have designated this three-year period as the “Profitability Phase through Accelerated Growth Investment.” In addition to prescription pharmaceuticals, we are promoting various initiatives across the healthcare sector – including medical devices and materials, reagents, OTC products, and customer support systems – to create new value through proactive alliances and other measures. Our goal is to transform into a “Comprehensive Healthcare Solutions Provider” that delivers this value to our business partners, customers, and patients.

Regarding progress on our Medium-term Management Plan during the first quarter, with the goal of achieving the numerical targets for the fiscal year ending March 2029, we have begun reviewing and implementing measures in line with the growth strategies of each business division, company-wide efficiency strategies, and strategies to strengthen our management foundation, and have started monitoring these efforts through the Management Strategy Committee.

・**Growth Strategies**

With the aim of increasing gross profit in our Pharmaceutical Wholesaling business, we have identified key challenges related to securing specialty pharmaceuticals and focusing on growth-driving products, and have begun implementing a new PDCA cycle to address these challenges.

Regarding alliances aimed at creating new businesses, in May we signed a memorandum of understanding on joint research with Kyowa Medical Corporation, which operates a medical device and materials wholesale business in the Tokai and Greater Tokyo areas.

In June, we signed a memorandum of understanding with DHL Supply Chain Japan, Inc., a member of the DHL Group – a global leader in contract logistics – regarding a partnership to provide comprehensive logistics solutions in Japan. Moving forward, we will integrate the group’s global logistics network and expertise in the life sciences and healthcare sectors with our group’s established pharmaceutical distribution network, and we will proceed with concrete discussions on strengthening manufacturer logistics and clinical trial logistics, as well as providing one-stop services for pharmaceutical distribution. Also in June, we invested in Rege Nephro Co., Ltd., a bio-tech venture engaged in research into and development of kidney regenerative medicine and drug discovery using iPS cells.

We acquired shares in Ishin Pharma Co., Ltd., with which we had long maintained a business partnership, in July of this year, making it a subsidiary. “AloStem® Sheet,” a regenerative medical product developed by the company for the treatment of epidermolysis bullosa, was listed in the NHI Drug Price Standards on July 15 and launched on July 27. For this product, we have established a system in which KYOSOMIRAI PHARMA handles shipment approval, while TOHO PHARMACEUTICAL CO., LTD. and its pharmaceutical wholesale subsidiaries manage the distribution process under strict temperature control. This marks the landmark first step toward the full-line specialty service that our Group aims to establish.

・**Efficiency Strategy**

We identified products and services that could help reduce costs and reviewed our business partners and contracts. In addition, we have begun exploring ways to improve productivity in our transportation and delivery operations, and we will promote measures with clearly specified cost savings. In addition, with regard to business process reform, we are currently implementing specific measures, starting with back-office operations.

・**Strengthening the Management Foundation**

Progress is being made on the overhaul of our core human resources system, and we plan to complete the transition to the new system during the second quarter. In addition, based on the results of the engagement survey, we are promoting the development and implementation of measures to create a better work environment across all companies and departments.

We reported on the progress of these initiatives at the Management Strategy Committee meeting held on July 22.

The Company’s consolidated operating results for the three months ended June 30, 2026 recorded 397,774 million yen for net sales (an increase of 5.8% year on year), 2,465 million yen for operating profit (a decrease of 35.8% year on year), 3,810 million yen for ordinary profit (a decrease of 14.1% year on year), and 2,355 million yen for profit attributable to owners of parent (a decrease of 29.8% year on year).

The outline of business segment operating results is as follows.

< Pharmaceutical wholesaling business >

With regard to price negotiations with medical institutions, we continue to strive to propose prices commensurate with the value of our products, in accordance with the "Guidelines for the Improvement of Commercial Transaction Practices of Ethical Drugs for Manufacturers, Wholesalers, and Medical Institutions / Pharmacies" established by the Ministry of Health, Labor and Welfare. In addition, this past July, TOHO PHARMACEUTICAL CO., LTD. underwent a major organizational restructuring and reorganized into a two-division structure consisting of Sales and Logistics. Under our new organizational structure, we will move forward with speed to achieve the goals of our new Medium-term Management Plan.

In the three months ended June 30, 2026, while sales of market-leading anticancer drugs and limited-handling products for selected wholesalers – such as specialty pharmaceuticals – grew steadily, net sales amounted to 384,570 million yen (an increase of 6.2% year on year) with segment profit (operating profit) of 3,110 million yen (a decrease of 25.1% year on year) due to the impact of rising procurement costs for pharmaceuticals.

< Dispensing pharmacy business >

In our Dispensing Pharmacy business, with an eye toward building a community comprehensive healthcare system, we actively advanced our initiatives in home healthcare, including the assignment of pharmacists specializing in home care. In addition, we have established prescription input centers in Niigata and Gunma Prefectures to reduce the need for manual labor and enhance the quality of pharmacists' patient-focused services. Furthermore, at some locations, we are promoting digital transformation in healthcare by means such as installing dispensing robots and automated check-in kiosks, and introducing AI-powered medication history systems in an effort to enhance store functions and improve productivity.

In the three months ended June 30, 2026, net sales amounted to 24,977 million yen (an increase of 1.5% year on year) with segment profit (operating profit) of 113 million yen (a decrease of 38.8% year on year) due to a decrease in the number of patient visits resulting from an increase in long-term prescriptions.

< Pharmaceutical manufacturing and sales business >

In June 2026, we launched three products across three generic drug ingredients. In addition, we have been engaged in the stable supply of high-quality and high value-added pharmaceuticals by strictly monitoring the quality of products based on our own verification system and establishing a planned production and procurement system linked to demand forecasting. In the three months ended June 30, 2026, net sales amounted to 2,953 million yen (an increase of 0.2% year on year) with segment profit (operating profit) of 91 million yen (an increase of 85.8% year on year).

< Other peripheral businesses >

In the other peripheral businesses, net sales for the three months under review amounted to 1,507 million yen (a decrease of 7.2% year on year) with segment profit (operating profit) of 46 million yen (a decrease of 68.8 % year on year).

(Note) Segment sales include inter-segment transactions.

(2) Explanation of Financial Position
(Assets)
Current assets increased 5.9% from the end of the previous consolidated fiscal year to 604,916 million yen, mainly with an increase in cash and deposits of 14,698 million yen, and an increase in notes and accounts receivable-trade of 11,165 million yen.
Non-current assets decreased 0.8% from the end of the previous consolidated fiscal year to 168,322 million yen, mainly with a decrease in investment securities of 2,715 million yen included in other under investments and other assets.
As a result, consolidated total assets increased 4.4% from the end of the previous consolidated fiscal year, to 773,239 million yen.
(Liabilities)
Current liabilities increased 9.3% from the end of the previous consolidated fiscal year to 482,825 million yen, mainly with an increase in notes and accounts payable-trade of 42,823 million yen.
Non-current liabilities decreased 11.3% from the end of the previous consolidated fiscal year to 24,219 million yen, mainly with a decrease in bonds payable of 1,753 million yen.
As a result, total liabilities increased 8.1 % from the end of the previous consolidated fiscal year, to 507,045 million yen.
(Net assets)
Total net assets decreased 2.0% from the end of the previous consolidated fiscal year to 266,193 million yen, mainly with a decrease in retained earnings of 5,932 million yen, despite a decrease in treasury shares of 2,098 million yen.

(3) Explanation of Consolidated Financial Forecasts and Other Forward-Looking Information
There are no changes in the projected consolidated results of operations for the first half of fiscal year ending March, 2027 and the full-term of the fiscal year published on May 13, 2026.

2. Quarterly Consolidated Financial Statements and Main Notes

(1) Quarterly Consolidated Balance Sheets

(Unit: million yen)

	As of March 31, 2026	As of June 30, 2026
Assets		
Current assets		
Cash and deposits	87,361	102,059
Notes and accounts receivable-trade	347,084	358,250
Securities	7,000	7,000
Merchandise and finished goods	89,823	97,286
Raw materials and supplies	152	132
Other	39,911	40,364
Allowance for doubtful accounts	-288	-176
Total current assets	571,044	604,916
Non-current assets		
Property, plant and equipment	89,140	88,697
Intangible assets		
Goodwill	89	67
Other	7,989	8,139
Total intangible assets	8,079	8,206
Investments and other assets		
Other	73,870	72,824
Allowance for doubtful accounts	-1,352	-1,405
Total investments and other assets	72,517	71,418
Total non-current assets	169,737	168,322
Total assets	740,781	773,239

(Unit: million yen)

	As of March 31, 2026	As of June 30, 2026
Liabilities		
Current liabilities		
Notes and accounts payable-trade	414,243	457,066
Short-term borrowings	474	553
Income taxes payable	6,443	2,528
Provision for bonuses	3,795	5,851
Provision for bonuses for directors	49	8
Asset retirement obligations	19	—
Other	16,893	16,816
Total current liabilities	441,920	482,825
Non-current liabilities		
Bonds payable	1,753	—
Long-term borrowings	5,282	5,346
Provision for loss on guarantees	566	—
Retirement benefit liability	2,847	2,895
Asset retirement obligations	3,003	3,042
Other	13,847	12,934
Total non-current liabilities	27,300	24,219
Total liabilities	469,221	507,045
Net assets		
Shareholders' equity		
Share capital	10,649	10,649
Capital surplus	45,212	45,216
Retained earnings	230,378	224,445
Treasury shares	-26,775	-24,676
Total shareholders' equity	259,465	255,635
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	16,417	14,917
Revaluation reserve for land	-4,572	-4,572
Total accumulated other comprehensive income	11,844	10,345
Share acquisition rights	123	122
Non-controlling interests	126	90
Total net assets	271,560	266,193
Total liabilities and net assets	740,781	773,239

(2) Quarterly Consolidated Profit and Loss Statement and Quarterly Consolidated Statements of Comprehensive Income

Quarterly Consolidated Profit and Loss Statement

[Cumulative Period for the Consolidated First Quarter]

(Unit: million yen)

	Three months ended June 30, 2025	Three months ended June 30, 2026
Net sales	375,813	397,774
Cost of sales	345,753	368,294
Gross profit	30,060	29,479
Selling, general and administrative expenses		
Remuneration, salaries and allowances for directors	10,702	10,831
Provision for bonuses	1,808	1,791
Provision for bonuses for directors	13	8
Retirement benefit expenses	75	96
Welfare expenses	2,008	2,126
Vehicle expenses	253	225
Provision of allowance for doubtful accounts	-4	-61
Depreciation	1,310	1,330
Amortization of goodwill	28	22
Rent expenses	2,035	2,118
Taxes and dues	492	647
Non-deductible temporary paid consumption tax expense	1,973	1,828
Other	5,518	6,049
Total selling, general and administrative expenses	26,217	27,013
Operating profit	3,842	2,465
Non-operating income		
Interest income	14	33
Dividend income	378	462
Reversal of provision for loss on guarantees	—	566
Other	343	382
Total non-operating income	736	1,443
Non-operating expenses		
Interest expenses	13	21
Share of loss of entities accounted for using equity method	29	1
Rental expenses on real estate	43	44
Other	55	31
Total non-operating expenses	142	98
Ordinary profit	4,436	3,810

(Unit: million yen)

	Three months ended June 30, 2025	Three months ended June 30, 2026
Extraordinary income		
Gain on sales of non-current assets	455	3
Gain on sale of investment securities	4	3
Reversal of provision for loss on Antimonopoly Act	371	—
Total extraordinary income	830	7
Extraordinary loss		
Loss on disposal of non-current assets	80	46
Loss on valuation of investment securities	151	—
Loss on extinguishment of tie-in shares	—	573
Other	—	1
Total extraordinary losses	231	621
Profit before income taxes	5,035	3,196
Income taxes-current	1,323	2,182
Income taxes-deferred	355	-1,339
Total income taxes	1,678	843
Profit	3,357	2,353
Profit attributable to non-controlling interests	3	-1
Profit attributable to owners of parent	3,353	2,355

Quarterly Consolidated Statements of Comprehensive Income
[Cumulative Period for the Consolidated First Quarter]

(Unit: million yen)

	Three months ended June 30, 2025	Three months ended June 30, 2026
Net profit	3,357	2,353
Other comprehensive income		
Valuation difference on available-for-sale securities	-507	-1,471
Share of other comprehensive income of entities accounted for using equity method	-12	-28
Total other comprehensive income	-520	-1,499
Comprehensive income	2,836	853
Comprehensive income attributable to:		
Comprehensive income attributable to owners of parent	2,832	855
Comprehensive income attributable to non-controlling interests	3	-1

(3) Notes Concerning Quarterly Consolidated Financial Statements

(Notes Concerning Premise of a Going Business)

Not applicable.

(Notes Concerning Material Changes in Shareholders' Equity)

Not applicable.

(Segmental Information)

I Previous consolidated first quarter (from April 1, 2025 to June 30, 2025)

1. Information about sales and profit or loss by reportable segment

	Reportable segments					Adjustments (million yen) (Note 1)	Amount on the quarterly consolidated profit and loss statement (million yen) (Note 2)
	Pharmaceutical Wholesaling (million yen)	Dispensing Pharmacy (million yen)	Pharmaceutical Manufacturing and Sales (million yen)	Other Peripheral Businesses (million yen)	Total (million yen)		
Net Sales							
(1) Sales to external customers	349,339	24,618	598	1,256	375,813	—	375,813
(2) Inter-segment sales	12,689	1	2,347	368	15,407	-15,407	—
Total	362,029	24,619	2,946	1,625	391,221	-15,407	375,813
Segment profit	4,155	184	49	148	4,538	-695	3,842

(Note) 1. The amount of the adjustments for segment profits shows the elimination of internal transactions and unrealized profit and corporate expenses not attributable to any reportable segment.
2. Segment profits are reconciled with operating profit on the quarterly consolidated statement of income.

2. Information about impairment losses on non-current assets or goodwill by reportable segment
Not applicable.

II This consolidated first quarter (from April 1, 2026 to June 30, 2026)

1. Information about sales and profit or loss by reportable segment

	Reportable segments					Adjustments (million yen) (Note 1)	Amount on the quarterly consolidated profit and loss statement (million yen) (Note 2)
	Pharmaceutical Wholesaling (million yen)	Dispensing Pharmacy (million yen)	Pharmaceutical Manufacturing and Sales (million yen)	Other Peripheral Businesses (million yen)	Total (million yen)		
Net Sales							
(1) Sales to external customers	371,392	24,975	250	1,155	397,774	—	397,774
(2) Inter-segment sales	13,177	2	2,703	352	16,235	-16,235	—
Total	384,570	24,977	2,953	1,507	414,009	-16,235	397,774
Segment profit	3,110	113	91	46	3,362	-896	2,465

(Note) 1. The amount of the adjustments for segment profits shows the elimination of internal transactions and unrealized profit and corporate expenses not attributable to any reportable segment.
2. Segment profits are reconciled with operating profit on the quarterly consolidated statement of income.

2. Information about impairment losses on non-current assets or goodwill by reportable segment
Not applicable.

(Notes Concerning Consolidated Statements of Cash Flows)

Quarterly consolidated statements of cash flows for the first quarter of the current fiscal year are not prepared. Depreciation (Including amortization of intangible assets excluding goodwill.) and amortization of goodwill for the first quarter of the current fiscal year are as follows.

	Three months ended June 30, 2025	Three months ended June 30, 2026
Depreciation	1,412 million yen	1,449 million yen
Amortization of goodwill	28 million yen	22 million yen